Ask AI
ProCE Banner Activity

Evoluzione delle terapie mirate per il linfoma diffuso a grandi cellule B recidivante/refrattario

PDF

Il panorama terapeutico per i pazienti affetti da linfoma diffuso a grandi cellule B (DLBCL) si sta evolvendo rapidamente, con diverse terapie mirate in fase di sperimentazione clinica. In questo commento, gli esperti affrontano questioni fondamentali relative all’attuale ruolo della gemcitabina in associazione con oxaliplatino nel DLBCL recidivante/refrattario, al potenziale curativo delle terapie con cellule CAR T rispetto agli anticorpi bispecifici, nonché alla selezione e alla sequenza delle terapie mirate a seguito di progressione della malattia durante la terapia con cellule CAR T nella gestione dei pazienti affetti da DLBCL recidivante/refrattario.

Released: August 17, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with DLBCL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate colleagues and patients on the mechanisms of action and rationales for using novel targeted therapies in DLBCL

  • Evaluate the potential clinical application of emerging evidence for novel targeted therapies in DLBCL

  • Recommend the optimal targeted treatment for each patient with DLBCL, considering subtype, comorbidities, expert recommendations, and available evidence

  • Identify patients with DLBCL who are eligible for clinical trials evaluating novel targeted therapies

Financial Disclosures

Primary Author

Elizabeth Budde, MD, PhD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Crispr, Genentech/Roche; researcher: AstraZeneca, Merck.

Gilles Salles, MD, PhD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, BeOne, Bristol Myers Squibb, Daiichi Sankyo, Genentech/Roche, Genmab, GSK, Incyte, Ipsen, Janssen, Kite/Gilead, Lilly, Merck, Novartis; researcher (paid to institution): AbbVie, Daiichi Sankyo, Genentech, Genmab, Ipsen, Janssen.

Pier Luigi Zinzani, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Bristol Myers Squibb, Daichii Sankyo, Incyte, Janssen, Kite, Kyowa Kirin, Merck Sharp & Dohme, Novartis, Nurix, Roche, Sobi, Takeda.